{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:etcamah:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Aema%3Aetcamah%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001653,
    "timestamp_received": "2026-11-09T16:14:19.921788Z",
    "timestamp_returned": "2026-11-09T16:14:19.923441Z",
    "trace_id": "49e87061-52a5-454a-b9da-efac195583c4"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:ema:etcamah:0",
      "type": "Indication",
      "description": "Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1-mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2026-08-02:0",
          "type": "Contribution",
          "description": "Initial curation of into moalmanac-db",
          "date": "2026-08-02",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2026-07-20:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2026-07-20",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:etcamah",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Etcamah (camizestrant) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca AB. Etcamah (camizestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/etcamah-epar-product-information_en.pdf. Revised July 2026. Accessed August 2, 2026.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/etcamah-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/etcamah"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca AB",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Etcamah",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "camizestrant",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2026-07-21",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2026-07-21",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": "EMEA/H/C/006494",
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The European Medicines Agency (EMA) has authorized camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1-mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor. The Product information further states that in pre- or perimenopausal women and in men, camizestrant plus a CDK4/6 inhibitor should be combined with a luteinizing hormone releasing hormone (LHRH) agonist or antagonist.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}